Targeted therapy with gefitinib or erlotinib for 2 years is better than chemotherapy as adjuvant in resected non small cell lung cancer stage l to llla with EGFR mutation. The result suggest better disease free survival, however overall survival data is yet to be reported. The trials supporting this are phase 2 SELECT trial and recently presented CTONG and EVANS trial.( recently presented in ASCO and WLCC). However in unselected patients ie. those without EGFR mutation there is no benefit of adjuvant TKI and chemotherapy with cisplatin vinorelbine is the gold standard.